Flexion's FX006 relieves arthritis knee pain in Phase IIb
This article was originally published in Scrip
Executive Summary
Flexion Therapeutics's locally-injected, sustained-release steroid FX006 significantly relieved pain and provided clinically meaningful benefit compared to the standard of care for patients with osteoarthritis of the knee in a Phase IIb clinical trial.